Default company panoramic image

IMBiotechologies Ltd. (IMB)

IMB is a Med Tech company with near term revenue opportunity for the first FDA cleared biodegradable embolic to treat vascularized tumors.

  • Stage Full Product Ready
  • Industry Biotechnology
  • Location Edmonton, AB, Canada
  • Currency CAD
  • Founded November 2008
  • Employees 3
  • Website

Company Summary

IMB is a privately held Canadian biotechnology company focused on commercializing medical device products in the area of embolotherapy. IMB’s lead product is OCL 500, the first biodegradable embolic particle cleared for marketing by the US FDA. Embolic agents are used to treat malignant (e.g. liver cancer) and non-malignant (e.g. uterine fibroids) solid hypervascularized tumors, and hyperplastic tissues (e.g. benign prostatic hyperplasia; BPH).


  • Default avatar
    Michael Stewart
    President & CEO

    Mr. Stewart has broad experience in the medical device and biopharmaceutical sector and has held positions as VP Research, VP Drug Development, Senior VP Operations and Chief Operating Officer. He has over 35 publications in peer-reviewed medical journals and is an inventor on several issued patents including IMB’s intellectual property.

  • Default avatar
    Irwin Griffith

    Dr. Griffith has over twenty years experience in the biotechnology sector. He has extensive hands-on experience in creating, managing and leading highly productive and effective teams in product development, discovery research, preclinical toxicology, manufacturing, business development and product commercialization. He has held Executive positions in project management, business development and product development.

  • Default avatar
    Jean-Paul Laurin
    Vice President, Business Development

    Mr. Laurin brings to IMB 15 years experience in the pharmaceutical, biotechnology and medical device industries, 10 of which have been spent in Business Development roles. His experience includes national and international product licensing, development and manufacturing agreements, as well as mergers, acquisitions and initial public offerings. Mr. Laurin has a BComm and M.Sc. degree from Concordia University in Montreal, Canada.


  • Default avatar
    Gordon Sustrik; Sustrik Law; Peter Inglis, Bennett Jones LLP
    Default avatar
    St. Arnaud Pinsent Steman, Chartered Accountants

Previous Investors

  • Default avatar
    Michael Stewart (Founder), |Irwin Griffith (Founder)
    Default avatar
    Accredited Investors (n=9)
    Default avatar
    Capital raised to date = $1,467,524